Top Markets
#1 Islamic Coin Islamic Coin +154.45%
#2 PulseChain PulseChain +48.38%
#3 Ergo Ergo +30.11%
#4 RedStone RedStone +16.56%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.64%
#6 SkyAI SkyAI +10.52%
#7 Siren Siren +8.99%
#8 Lighter Lighter +8.81%
#9 Monad Monad +8.67%
#10 OPENLOOT OPENLOOT +8.16%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Classifica tra le azioni #28046
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Prezzo delle azioni
$0.55
Ultima sincronizzazione: 2025-02-11
Capitalizzazione di mercato
$28.90M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Marinus Pharmaceuticals, Inc. (MRNS)

Categoria

Healthcare
Numero di azioni in circolazione per Marinus Pharmaceuticals, Inc. (MRNS)
Numero di azioni in circolazione al September 2024: 57.23M
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Marinus Pharmaceuticals, Inc., il numero attuale di azioni in circolazione è 57.23M. Alla fine del December 2022, la società aveva 39.07M azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Marinus Pharmaceuticals, Inc. (MRNS) dal 2012 al 2026
Azioni in circolazione alla fine di ogni anno
Anno Azioni in circolazione Cambia
2026 (TTM) 57.23M 6.48%
2023 53.75M 37.56%
2022 39.07M 6.47%
2021 36.70M 34.57%
2020 27.27M 100.10%
2019 13.63M 33.30%
2018 10.22M 73.72%
2017 5.89M 20.73%
2016 4.87M 30.69%
2015 3.73M 142.49%
2014 1.54M -23.70%
2013 2.02M 0.00%
2012 2.02M 0.00%
Azioni in circolazione per aziende simili o concorrenti
Azienda Azioni in circolazione Differenza Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 343.65%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 591.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M 8.66%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 744.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH